Corona Remedies Q1 FY27 Earnings Call — Analysis (NSE: CORONA)
Corona Remedies Q1 FY27 revenue grows 21.9% YoY to ₹422 Cr, EBITDA margin expands 190 bps to 22%, outperforming IPM across all therapies.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹422 Cr ( +21.9% YoY ) . New guidance — FY27 fy27 organic revenue growth 15% . New story: Broad-based domestic outperformance vs IPM .
Results
Revenue ₹422 Cr +21.9% YoY; EBITDA ₹93 Cr +33.5% YoY; EBITDA margin 22% (+190 bps); PAT ₹60 Cr +30.1% YoY; India business growth 22.7%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹422 Cr | +21.9% | yoy · Q1FY27 |
| EBITDA | ₹93 Cr | +33.5% | yoy · Q1FY27 |
| PAT | ₹60 Cr | +30.1% | yoy · Q1FY27 |
| EBITDA Margin | 22% | +190 bps | yoy · Q1FY27 |
| PAT Margin | 14.2% | +90 bps | yoy · Q1FY27 |
| India Business Revenue Growth | 22.7% | +22.7% | yoy · Q1FY27 |
| Organic Revenue Growth (ex-Wokadine) | 21.4% | +21.4% | yoy · Q1FY27 |
| Chronic Revenue Share | 73.4% | point_in_time · Q1FY27 · Q1FY27 |
Guidance
FY27 guidance reiterated: 15% organic revenue growth, 1.5-2% inorganic, targeting ~17% total revenue growth and 20% PAT growth; Wokadine target 25% growth off ₹20 Cr base.
What management committed to
- [Corona Remedies] targets 15% organic revenue growth for FY27. — 15%, FY27
- [Corona Remedies] targets 20% PAT growth for FY27. — 20%, FY27
- [Corona Remedies] expects approximately 17% total revenue growth in FY27, comprising 15% organic and 1.5-2% inorganic growth. — ~17%, FY27
- [Corona Remedies] targets 25% revenue growth for [Wokadine brand] in FY27 from a base of ₹20 Cr internal revenue. — 25% growth from INR 20 crores base, FY27
- [Corona Remedies] expects asset turnover of the new EU-GMP hormone facility to be less than 1x in FY27, increasing to approximately 3x over the next three years. — <1x in FY27, ~3x thereafter, FY29
- [Corona Remedies'] international revenue share will increase from 3% to high single-digit in three to four years, driven by the new hormone facility. — high single digit, FY30
- [Corona Remedies] will add 200-250 medical representatives (6-8% increase) annually beyond FY27. — 200-250 MRs, FY28
Key themes
Broad-based outperformance, margin expansion, and EU-GMP hormone facility commissioning.
How the narrative shifted
- Broad-based domestic outperformance vs IPM: Management positions Corona as the fastest-growing top-30 pharma company, with volume, price, and new product growth all significantly ahead of IPM, driven by strong brand equity and field force.
- EU-GMP hormone facility as competitive moat: The newly commercialised Europe-GMP hormone facility is portrayed as a unique, complex-manufacturing advantage that will strengthen domestic leadership in Women’s Healthcare and unlock regulated export markets.
- Margin expansion with cautious sustainability: Management highlights 190 bps margin expansion from favourable product mix and operating leverage but carefully tempers expectations citing geopolitical input-cost risks.
- Chronic portfolio dominance: Chronic and semi-chronic therapies now 73.4% of portfolio; management frames this as a sticky, high-prescription base that supports above-market growth and pricing power.
- Inorganic growth engine with Wokadine and bolt-on acquisitions: Acquired brands like Wokadine are being integrated into the brand-building engine, with clear growth targets; management signals appetite for further in-licensing and acquisitions.
- Geopolitical raw material cost headwinds: Management acknowledges Southeast Asia geopolitical disturbance started Feb 2026 and may cause a 100 bps cost headwind, but expects to offset via operational efficiencies to protect PAT growth.
- India-first focus with export as long-term optionality: Despite EU-GMP facility and dossier filings, management insists domestic business will remain >90% for next 3-5 years, framing exports as a gradual upside.
Operational commentary
- Commissioned EU-GMP approved women’s hormone manufacturing facility, enabling complex hormonal products across tablets, soft gelatin capsules, ointments, and gels; positioned as cornerstone for domestic leadership and future exports.
- Significantly outperformed IPM: India business grew 22.7% vs IPM 11.6%; MAT volume growth 6.3% (5x IPM), price-led growth 8.7% vs IPM 5.6%, new product contribution 3.4% vs IPM 2.9%.
- Scaled engine brands: now two brands with annual revenue >₹100 Cr and >40 brands >₹10 Cr, up from 32 brands in MAT June 2023.
- Renewed EU-GMP certification for Ahmedabad oral solid dosage facility under 'one world one quality' philosophy, strengthening domestic and regulated export readiness.
- Launched dedicated IVF taskforce within Gynecology/Women’s Healthcare to deepen penetration and build a sustainable growth platform.
- Integrated Wokadine (acquired last day of FY26) into brand-building strategy; realigned field force; Bayer-Zydus portfolio Noklot launched in cardio-metabolic, recovering full ₹7 Cr acquisition cost in Q1.
- Strengthened R&D investment and team augmentation focused on process efficiencies, differentiated formulations, and new product opportunities across core therapies.
- Domestic manufacturing share ~60:40 in-house/outsourced; new hormone facility expected to lift in-house share while maintaining ~60:40 in FY27.
Analyst Q&A
Q. Sustainability of current margin profile given 20%+ growth, and potential for operating leverage over two-to-three years.
Margin improvement driven by favorable product mix and operating leverage; however, geopolitical Southeast Asia risk creates input cost volatility. Premature to comment on sustainability of current levels, but endeavor to maintain margins within a similar range. Guidance of 20% PAT growth remains unchanged.
Q. Quarterly split of 21.9% organic growth between volume, price, and new launches.
Extrapolate from MAT June 2026 split: volume 6.3%, price 8.7%, new products 3.4%; quarterly mix is near to the same.
Q. Impact of higher raw material prices in Q1 given geopolitical disruption, and expected timing of impact.
Minimal impact in Q1 due to 70-90 days of inventory; beginning to see new stocks from June. A 100 bps hit possible; managing other operating costs to protect PAT growth guidance.
Q. Wokadine sales appear lower YoY in Q1; corrective steps taken.
First quarter used for supply-chain integration; not representative of future quarters. Targeting 25% growth commitment in coming quarters.
Q. How much cost from the new hormone plant is sitting in the P&L, and under-recoveries.
Hormone costs were already in P&L from earlier Solan facility; new plant capex was capitalized. Depreciation impact minimal (~₹6.5 Cr/year). Revenue from hormone products continues; asset turn <1x this year.
Research and educational content only. Not investment advice.